Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($1.86), in-line with the analyst estimate of ($1.86). Revenue for the quarter came in at $27.3 million versus the consensus estimate of $19.01 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.